Updated data from a late-stage trial of voxelotor fell shy of investors' expectations.
News & Analysis: Global Blood Therapeutics
Investors will get additional insight into a potential new treatment for sickle cell disease on Friday.
Investors hope that its lead drug candidate can make it to the Food and Drug Administration for approval soon.
The company reported boring third-quarter 2018 operating results, but followed up with important clinical updates in the first week of December.
Positive trial data unveiled at the American Society of Hematology conference makes these top stocks to watch in 2019.
Shares jump after the company releases upbeat clinical data and regulatory news.
If you don't consider adding these biotech stocks to your portfolio this month, you could wind up missing out on an opportunity.
There's a possibility that the FDA might be willing to take an early look at the company's lead drug candidate.
Find out which of these stocks took the biggest hit.
Shares plunged after the company released clinical data. Here's what investors need to know.